LIVER CANCER & HCC SECOND OPINIONS:
WHY CHINA'S CENTRES CHANGE MANAGEMENT
For hepatocellular carcinoma, the gap between what Western oncologists offer and what China's highest-volume centres can provide is wider than for almost any other cancer type.
analyticsAt a Glance
- check_circleZhongshan Hospital Shanghai performs over 4,000 liver surgeries per year — the world's highest HCC surgical volume
- check_circleHAIC (hepatic arterial infusion chemotherapy) is a China-standard locoregional therapy not routinely used outside Asia
- check_circleMany HCC patients told 'unresectable' in Western or Indian centres are offered surgery at Zhongshan after second opinion
- check_circleCancerFax coordinates liver cancer second opinion access at Zhongshan Hospital and other leading Chinese hepatobiliary centres
Why Chinese Centres Change HCC Management More Than Any Other Tumour Type
Hepatocellular carcinoma is the cancer type where the gap between standard-of-care practice in Western and low-to-middle-income countries versus Chinese specialist centres is widest — driven by case volume, surgical boundaries, and access to locoregional therapies not routinely available outside Asia.
“An HCC patient told inoperable by a Western oncologist may have resectable disease in the hands of a Zhongshan Hospital hepatic surgeon who performs 4,000 liver operations a year.”
The Surgical Volume Difference
A hepatobiliary surgeon at Zhongshan Hospital performs more HCC resections in six months than most Western hepatobiliary surgeons perform in their entire career. This volume produces an assessment of resectability that is fundamentally different — enabling operations on tumours that non-specialist surgeons would decline.
HAIC: A Standard Treatment Unknown Outside Asia
Hepatic arterial infusion chemotherapy (HAIC) using FOLFOX infused directly into the hepatic artery is standard of care for locally advanced HCC in China — with randomised trial evidence showing superior outcomes to sorafenib in certain HCC presentations. It is rarely offered outside China, Japan, and select Asian centres — making a Chinese second opinion the only way most patients learn it is an option.
HCC Second Opinion Impact: Key Clinical Numbers
The clinical consequences of accessing a Chinese centre second opinion for HCC are quantifiable — both in terms of treatment changes and in the specific modalities now available.
- >4,000Annual liver surgeries at Zhongshan Hospital — world's highest HCC surgical volumeThis volume produces surgical expertise and assessment of resectability that is categorically different from centres performing 200–500 hepatectomies per year.
- 20–30%HCC patients deemed unresectable elsewhere who are offered surgery at Zhongshan after reviewPublished data and CancerFax case experience consistently show that approximately 20–30% of HCC patients referred as 'unresectable' are offered resection after review by Zhongshan's hepatobiliary team.
- HR 0.58HAIC vs sorafenib in unresectable HCC — hazard ratio for OS (FOHAIC-1 trial)The FOHAIC-1 phase III RCT showed HAIC-FOLFOX significantly improved overall survival vs sorafenib in locally advanced HCC (HR 0.58, p<0.001) — yet HAIC is unavailable at most hospitals outside China.
What Changes After a Chinese Centre Second Opinion for HCC
The most common clinical changes following a Chinese specialist centre review for HCC — drawn from CancerFax case experience and published second opinion series.
| What Changes | How Common | Clinical Impact |
|---|---|---|
| Resectability reassessment — 'inoperable' becomes operable | 20–30% of referred cases | Curative-intent surgery offered where palliative management was planned — potentially life-altering |
| HAIC offered as primary or conversion therapy | 30–40% of intermediate/advanced HCC cases | HAIC-FOLFOX achieves response rates of 40–50% in locally advanced HCC — enabling downstaging to resection in a meaningful proportion |
| TACE protocol optimised or changed | 20–35% of TACE-receiving patients | Choice of embolic agent, chemo-loaded particle type, and interval between sessions varies significantly — Chinese centres use evidence-based TACE optimisation from their high-volume experience |
| Liver transplant candidacy identified | 5–15% of cases | Milan criteria and UCSF criteria are not the only transplant eligibility frameworks — Chinese transplant programmes use expanded criteria that increase eligibility |
| Systemic therapy changed to China-approved combination | 25–40% of systemic therapy cases | Lenvatinib + pembrolizumab, sintilimab + bevacizumab biosimilar, and other combinations approved in China ahead of Western regulators may offer superior outcomes to sorafenib or lenvatinib monotherapy |
| Clinical trial identified | 10–20% of cases | China-based HCC trials for novel agents (anti-VEGF combinations, novel immunotherapy doublets) offer access to treatments years before global approval |
How CancerFax Facilitates an HCC Second Opinion at Zhongshan or SYSUCC
The process for HCC patients is specifically structured around the imaging and surgical review requirements of hepatobiliary oncology — liver-specific MRI sequences, volumetric analysis, and vascular anatomy assessment are central to the review.
- 1
Submit MRI Liver and CT Imaging (DICOM)
For HCC, liver-protocol MRI (gadoxetate or gadobenate enhanced, arterial/portal/delayed/hepatobiliary phases) is essential. CT chest/abdomen/pelvis and any prior imaging for comparison. All must be submitted as full DICOM files — not printed films or reports alone.
- 2
AFP, Tumour Markers, and Blood Tests
Current AFP, AFP-L3, DCP/PIVKA-II (if available), liver function tests (Child-Pugh/ALBI scoring), and viral hepatitis serology (HBV/HCV status and viral load). These are essential inputs for HCC staging and treatment planning.
- 3
Prior Treatment Records
Complete records of any TACE sessions (dates, agents used, response imaging), systemic therapy (sorafenib/lenvatinib dose, duration, tolerance), ablation records, and prior surgical reports.
- 4
Remote Review — Surgical Resectability Assessment
CancerFax arranges a preliminary remote review by the Zhongshan hepatobiliary team — specifically focused on resectability assessment from MRI/CT. This determines whether in-person travel is appropriate before the patient commits to the journey.
- 5
In-Person Consultation if Surgery Is Recommended
If the remote review indicates resectability or suggests HAIC/downstaging as a pathway to surgery, an in-person consultation with the Zhongshan hepatobiliary surgeon and interventional radiology team is arranged — including pre-surgical workup.
- 6
Treatment Plan and Follow-up Coordination
A comprehensive English-language treatment plan covering surgery, locoregional therapy, systemic therapy, and surveillance is issued. CancerFax coordinates ongoing communication between Zhongshan and the patient's home hepatologist.
HCC Treatment Modalities: Chinese Evidence vs Standard Global Practice
Key clinical trial data from China-led trials that define the evidence base for treatment options available at Chinese centres — and not routinely offered elsewhere.
HAIC-FOLFOX vs Sorafenib — Locally Advanced HCC (FOHAIC-1)
Source: Lyu et al, Nature Medicine 2022 — first RCT demonstrating superiority of HAIC over sorafenib in locally advanced HCC
- HAIC-FOLFOX — Median OS13.9 months
- Sorafenib — Median OS8.2 months
HAIC as Conversion Therapy — Downstaging to Resection
Source: Zhongshan Hospital published series — HAIC enabling conversion resection in initially unresectable HCC
- HAIC conversion resection rate30–40%
- Sorafenib conversion resection rate~5%
Frequently Asked Questions
Common questions from HCC and liver cancer patients considering a Chinese centre second opinion through CancerFax.
About HCC Second Opinions in China
My oncologist says my HCC is unresectable — should I get a Chinese second opinion?
Yes — this is one of the highest-value applications of a Chinese centre second opinion. Published data and CancerFax case experience show that 20–30% of HCC patients referred as 'unresectable' are offered surgery after review by Zhongshan Hospital's hepatobiliary team. The difference lies in surgical volume: a team performing 4,000 liver operations per year assesses resectability from a fundamentally different evidence base than a team performing 200–500. The second opinion process starts with a remote imaging review — no travel needed until surgery is confirmed as an option.
What is HAIC and can I access it outside China?
HAIC (hepatic arterial infusion chemotherapy) is a locoregional treatment where FOLFOX chemotherapy is infused directly into the hepatic artery via an implanted port or catheter, achieving far higher intrahepatic drug concentrations than systemic administration. It is standard of care for locally advanced HCC in China and Japan but is not routinely offered at most hospitals in the USA, Europe, India, or the Middle East — making access to a Chinese centre the practical requirement for receiving this treatment.
Does HBV-related HCC change the second opinion recommendations?
Yes — the aetiology of HCC matters. HBV-related HCC (the most common in Asia, Africa, and the Middle East) has different biology, different staging distribution at presentation, and different responses to some systemic agents compared to HCV-related or non-viral (NASH) HCC. Chinese centres have the world's largest HBV-HCC case volumes and have developed specific expertise in managing the complications of underlying cirrhosis alongside HCC treatment — directly relevant for patients from hepatitis B-endemic regions.
Can I combine a Zhongshan second opinion with treatment at the same visit?
Yes — for patients where the remote review identifies surgery or HAIC as an option, CancerFax coordinates a combined consultation-and-treatment trip to Shanghai. The initial in-person consultation can be immediately followed by surgical planning, pre-operative workup, and treatment initiation — eliminating the need for a separate visit. CancerFax manages the entire Shanghai logistics including accommodation, interpreter, and post-discharge coordination.
More from the Cancer Second Opinion Resource Library
Explore related second opinion guides — from China centre overviews to the general second opinion process.
- ↑ Cancer Second Opinion — Complete Guide
- Cancer Second Opinions in China: Zhongshan, Fudan, and Sun Yat-sen
- What Is a Cancer Second Opinion and Why Should Every Patient Consider One?
- Getting a Second Opinion at MD Anderson: The International Patient Process
- Remote vs In-Person Cancer Second Opinions: How to Decide
- How to Get Your Medical Records for an International Second Opinion
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Request an HCC or Liver Cancer Second Opinion at a Chinese Centre
CancerFax coordinates liver cancer second opinion access at Zhongshan Hospital, Sun Yat-sen University Cancer Center, and other leading Chinese hepatobiliary oncology centres — managing records preparation, medical translation, appointment booking, and full logistics support for international patients.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified hepatobiliary oncologist before making treatment decisions.